title: A higher CD105-assessed microvessel density and worse prognosis in elderly patients with laryngeal carcinoma.
abstract: OBJECTIVE
  To ascertain the prognostic role of endoglin (CD105)-assessed microvessel density (MVD) in patients older than 65 years with laryngeal squamous cell carcinoma (LSCC), and whether this MVD differed in the elderly patients from younger adult controls.
  
  
  METHODS
  Retrospective clinicopathologic investigation.
  
  
  METHODS
  Academic tertiary referral center.
  
  
  METHODS
  Fifty-seven consecutive elderly patients with LSCC and 19 younger adult controls.
  
  
  METHODS
  Image analysis of immunohistochemical reactions.
  
  
  RESULTS
  In LSCCs in elderly patients, N+ stage correlated with a shorter disease-free survival (DFS) (P < .001). A higher CD105-assessed MVD was associated with disease recurrence (P = .006). The DFS was shorter in elderly patients whose CD105 expression was greater than 9.6% than in patients whose CD105 expression was 9.6% or less (P = .001). Among the elderly patients with tumors staged as N0, a higher CD105-assessed MVD correlated with disease recurrence (P = .006) and a shorter DFS (P = .001). CD105-assessed MVD in LSCC occurring in elderly patients did not differ from the situation observed in younger adult controls (P = .74).
  
  
  CONCLUSIONS
  In LSCC occurring in elderly patients, CD105-assessed MVD may be a useful N-stage independent, angiogenic prognostic marker for pinpointing: (1) patients at higher risk of disease recurrence; and (2) patients with N0 tumors at higher risk of early recurrence, who may benefit from more aggressive therapy.
authors.affiliation: Department of Medical and Surgical Specialties, Otolaryngology Section, University of Padova, Via Giustiniani 2, 35128 Padova, Italy. gino.marioni@unipd.it
authors.forename: Gino
authors.initials: G
authors.lastname: Marioni
authors.forename: Alberto
authors.initials: A
authors.lastname: Staffieri
authors.forename: Enzo
authors.initials: E
authors.lastname: Manzato
authors.forename: Giovanni
authors.initials: G
authors.lastname: Ralli
authors.forename: Marco
authors.initials: M
authors.lastname: Lionello
authors.forename: Luciano
authors.initials: L
authors.lastname: Giacomelli
authors.forename: Vlatko
authors.initials: V
authors.lastname: Prosenikliev
authors.forename: Rosario
authors.initials: R
authors.lastname: Marchese-Ragona
authors.forename: Alessandra
authors.initials: A
authors.lastname: Busnardo
authors.forename: Francesco
authors.initials: F
authors.lastname: Bolzetta
authors.forename: Stella
authors.initials: S
authors.lastname: Blandamura
mesh_terms: D000368:Aged; D015703:Antigens, CD / Q000032:analysis*; D014408:Biomarkers, Tumor / Q000032:analysis; D002294:Carcinoma, Squamous Cell / Q000098:blood supply* / Q000401:mortality / Q000473:pathology / Q000628:therapy; D016022:Case-Control Studies; D000071063:Endoglin; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D007822:Laryngeal Neoplasms / Q000098:blood supply* / Q000401:mortality / Q000473:pathology / Q000628:therapy; D008297:Male; D055806:Microvessels / Q000473:pathology*; D009364:Neoplasm Recurrence, Local / Q000473:pathology*; D009389:Neovascularization, Pathologic / Q000473:pathology; D011379:Prognosis; D011956:Receptors, Cell Surface / Q000032:analysis*; D012189:Retrospective Studies
chemical_list: D015703:Antigens, CD; D014408:Biomarkers, Tumor; C064206:ENG protein, human; D000071063:Endoglin; D011956:Receptors, Cell Surface